Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma is a lethal cancer with fewer than 7% of patients surviving past 5 years. T-cell immunity has been linked to the exceptional outcome of the few long-term survivors, yet the relevant antigens remain unknown. Here we use genetic, immunohistochemical and transcriptional immunoprofiling, computational biophysics, and functional assays to identify T-cell antigens in long-term survivors of pancreatic cancer. Using whole-exome sequencing and in silico neoantigen prediction, we found that tumours with both the highest neoantigen number and the most abundant CD8+ T-cell infiltrates, but neither alone, stratified patients with the longest survival. Investigating the specific neoantigen qualities promoting T-cell activation in long-term survivors, we discovered that these individuals were enriched in neoantigen qualities defined by a fitness model, and neoantigens in the tumour antigen MUC16 (also known as CA125). A neoantigen quality fitness model conferring greater immunogenicity to neoantigens with differential presentation and homology to infectious disease-derived peptides identified long-term survivors in two independent datasets, whereas a neoantigen quantity model ascribing greater immunogenicity to increasing neoantigen number alone did not. We detected intratumoural and lasting circulating T-cell reactivity to both high-quality and MUC16 neoantigens in long-term survivors of pancreatic cancer, including clones with specificity to both high-quality neoantigens and predicted cross-reactive microbial epitopes, consistent with neoantigen molecular mimicry. Notably, we observed selective loss of high-quality and MUC16 neoantigenic clones on metastatic progression, suggesting neoantigen immunoediting. Our results identify neoantigens with unique qualities as T-cell targets in pancreatic ductal adenocarcinoma. More broadly, we identify neoantigen quality as a biomarker for immunogenic tumours that may guide the application of immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In rare patients with localized PDAC who are long-term survivors, bacteria can translocate from the intestine into the tumour and control anti-tumour immune activation11,12.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [12]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, the gut microbiota can indirectly increase the immunogenicity of tumor cells by providing tumor cross-antigens to promote the efficacy of ICI [50, 68, 69].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PDAC tumors from long term survivors have high quantity and quality of neoantigens, and stronger infiltration and activation of CD8+ T cells”
From Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes (2019) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These data suggest that microbial host factors, independent of the genomic composition of the tumor, may determine tumor behavior and patient outcomes.”
From Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes (2019) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Significantly, the aggressive progression of PDAC, characterized by immune evasion and therapeutic resistance, is heavily influenced by the TME (Balachandran et al., 2017).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The Ensembl Variant Effect Predictor
McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Self-citationWhole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
Ino, Y., Yamazaki-Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 849
Gros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., Prickett, T. D., Gartner, J. J., Crystal, J. S., Roberts, I. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4051 · Cited by 829
Cited by
Items 101–200 of 1,001
Trovato, R., Fiore, A., Sartori, S., Canè, S., Giugno, R., Cascione, L., Paiella, S., Salvia, R., De Sanctis, F., Poffe, O., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0734-6 · Cited by 189
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
Chamoto, K., Yaguchi, T., Tajima, M., & Honjo, T. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00867-9 · Cited by 185
“microbiota and tumour antigens 167,168 ; and (3) microbiota translocation to organs to activate peripheral immunity 169,170 .”
BackgroundCommensal bacteria stimulate antitumor responses via T cell cross-reactivity
Bessell, C. A., Isser, A., Havel, J. J., Lee, S., Bell, D. R., Hickey, J. W., Chaisawangwong, W., Glick Bieler, J., Srivastava, R., Kuo, F., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.135597 · Cited by 184
Self-citationNew Insights Into the Cancer–Microbiome–Immune Axis: Decrypting a Decade of Discoveries
Jain, T., Sharma, P., Are, A. C., Vickers, S. M., & Dudeja, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.622064 · Cited by 183
Salem, M. E., Puccini, A., Xiu, J., Raghavan, D., Lenz, H.-J., Korn, W. M., Shields, A. F., Philip, P. A., Marshall, J. L., & Goldberg, R. M. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0143 · Cited by 185
Tumor microbiome links cellular programs and immunity in pancreatic cancer
Ghaddar, B., Biswas, A., Harris, C., Omary, M. B., Carpizo, D. R., Blaser, M. J., & De, S. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.009 · Cited by 181
Arginase 1 is a key driver of immune suppression in pancreatic cancer
Menjivar, R. E., Nwosu, Z. C., Du, W., Donahue, K. L., Hong, H. S., Espinoza, C., Brown, K., Velez-Delgado, A., Yan, W., Lima, F., et al. (2023) · eLife · doi:10.7554/elife.80721 · Cited by 177
Kabacaoglu, D., Ciecielski, K. J., Ruess, D. A., & Algül, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01878 · Cited by 179
Schmidt, J., Smith, A. R., Magnin, M., Racle, J., Devlin, J. R., Bobisse, S., Cesbron, J., Bonnet, V., Carmona, S. J., Huber, F., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100194 · Cited by 174
Tumour mutational burden: clinical utility, challenges and emerging improvements
Budczies, J., Kazdal, D. N., Menzel, M., Beck, S., Kluck, K., Altbürger, C., Schwab, C., Allgäuer, M., Ahadova, A., Kloor, M., et al. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00932-9 · Cited by 218
Gut microbiome in modulating immune checkpoint inhibitors
Li, X., Zhang, S., Guo, G., Han, J., & Yu, J. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104163 · Cited by 168
Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis
Lin, J. H., Huffman, A. P., Wattenberg, M. M., Walter, D. M., Carpenter, E. L., Feldser, D. M., Beatty, G. L., Furth, E. E., & Vonderheide, R. H. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190673 · Cited by 178
Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?
Derosa, L., Routy, B., Desilets, A., Daillère, R., Terrisse, S., Kroemer, G., & Zitvogel, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0236 · Cited by 170
Orhan, A., Vogelsang, R. P., Andersen, M. B., Madsen, M. T., Hölmich, E. R., Raskov, H., & Gögenur, I. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.013 · Cited by 173
Quaranta, V., Rainer, C., Nielsen, S. R., Raymant, M. L., Ahmed, M. S., Engle, D. D., Taylor, A., Murray, T., Campbell, F., Palmer, D. H., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3876 · Cited by 168
Kinkead, H. L., Hopkins, A., Lutz, E., Wu, A. A., Yarchoan, M., Cruz, K., Woolman, S., Vithayathil, T., Glickman, L. H., Ndubaku, C. O., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122857 · Cited by 166
Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)
Markosyan, N., Li, J., Sun, Y. H., Richman, L. P., Lin, J. H., Yan, F., Quinones, L., Sela, Y., Yamazoe, T., Gordon, N., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127755 · Cited by 170
Aaes, T. L., & Vandenabeele, P. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00658-y · Cited by 169
Gut microbiota shapes cancer immunotherapy responses
Lei, W., Zhou, K., Lei, Y., Li, Q., & Zhu, H. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00786-8 · Cited by 195
Liudahl, S. M., Betts, C. B., Sivagnanam, S., Morales-Oyarvide, V., da Silva, A., Yuan, C., Hwang, S., Grossblatt-Wait, A., Leis, K. R., Larson, W., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0841 · Cited by 164
The many faces of p53: something for everyone
Levine, A. J. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz026 · Cited by 163
“Thus, the frequencies with which different mutant p53 alleles are observed in many human cancers occur over a four log difference in their levels (Balachandran et al., 2017; Levine, 2019).”
BackgroundSelf-citationLi, L., Zou, J., Dai, Y., Fan, W., Niu, G., Yang, Z., & Chen, X. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0599-5 · Cited by 161
Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different
Lee, C.-H., Yelensky, R., Jooss, K., & Chan, T. A. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.04.005 · Cited by 162
Self-citationDe Mattos-Arruda, L., Vazquez, M., Finotello, F., Lepore, R., Porta, E., Hundal, J., Amengual-Rigo, P., Ng, C. K. Y., Valencia, A., Carrillo, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.008 · Cited by 157
Self-citationVäyrynen, S. A., Zhang, J., Yuan, C., Väyrynen, J. P., Dias Costa, A., Williams, H., Morales-Oyarvide, V., Lau, M. C., Rubinson, D. A., Dunne, R. F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3141 · Cited by 160
Self-citationTargeting galectin-1 inhibits pancreatic cancer progression by modulating tumor–stroma crosstalk
Orozco, C. A., Martinez-Bosch, N., Guerrero, P. E., Vinaixa, J., Dalotto-Moreno, T., Iglesias, M., Moreno, M., Djurec, M., Poirier, F., Gabius, H.-J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1722434115 · Cited by 158
Development of Peptide-Based Vaccines for Cancer
Abd-Aziz, N., & Poh, C. L. (2022) · Journal of Oncology · doi:10.1155/2022/9749363 · Cited by 152
Bystander T cells in cancer immunology and therapy
Meier, S. L., Satpathy, A. T., & Wells, D. K. (2022) · Nature Cancer · doi:10.1038/s43018-022-00335-8 · Cited by 172
Self-citationMulti-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
HEPAVAC Consortium, Löffler, M. W., Mohr, C., Bichmann, L., Freudenmann, L. K., Walzer, M., Schroeder, C. M., Trautwein, N., Hilke, F. J., Zinser, R. S., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0636-8 · Cited by 160
Wu, J., Wang, W., Zhang, J., Zhou, B., Zhao, W., Su, Z., Gu, X., Wu, J., Zhou, Z., & Chen, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02559 · Cited by 150
Self-citationCarpenter, E. S., Elhossiny, A. M., Kadiyala, P., Li, J., McGue, J. J., Griffith, B. D., Zhang, Y., Edwards, J., Nelson, S., Lima, F., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0013 · Cited by 171
Richman, L. P., Vonderheide, R. H., & Rech, A. J. (2019) · Cell Systems · doi:10.1016/j.cels.2019.08.009 · Cited by 152
The breakthrough of the microbiota
Kroemer, G., & Zitvogel, L. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2018.4 · Cited by 147
Romero, J. M., Grünwald, B., Jang, G.-H., Bavi, P. P., Jhaveri, A., Masoomian, M., Fischer, S. E., Zhang, A., Denroche, R. E., Lungu, I. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2803 · Cited by 146
Strobel, O., Lorenz, P., Hinz, U., Gaida, M. M., König, A., Hank, T. P., Niesen, W., Kaiser, J., Al‐Saeedi, M., Bergmann, F., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004147 · Cited by 165
Cancer Immunoediting in the Era of Immuno-oncology
Gubin, M. M., & Vesely, M. D. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1804 · Cited by 184
The Tumor Microbiome in Pancreatic Cancer: Bacteria and Beyond
McAllister, F., Khan, M. A. W., Helmink, B., & Wargo, J. A. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.11.004 · Cited by 138
Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer
Goehrig, D., Nigri, J., Samain, R., Wu, Z., Cappello, P., Gabiane, G., Zhang, X., Zhao, Y., Kim, I.-S., Chanal, M., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317570 · Cited by 131
The biological underpinnings of therapeutic resistance in pancreatic cancer
Beatty, G. L., Werba, G., Lyssiotis, C. A., & Simeone, D. M. (2021) · Genes & Development · doi:10.1101/gad.348523.121 · Cited by 159
The dark side of tumor-associated endothelial cells
Sanctis, F. D., Ugel, S., Facciponte, J. G., & Facciabene, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.02.002 · Cited by 144
Recent advances in therapeutic cancer vaccines
Zaidi, N., Jaffee, E. M., & Yarchoan, M. M. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00820-z · Cited by 163
Recent insights into the biology of pancreatic cancer
Yao, W., Maitra, A., & Ying, H. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102655 · Cited by 145
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi, M., Bartholin, L., & Neuzillet, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i20.2137 · Cited by 133
Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies
Liu, L., Kshirsagar, P. G., Gautam, S. K., Gulati, M., Wafa, E. I., Christiansen, J. C., White, B. M., Mallapragada, S. K., Wannemuehler, M. J., Kumar, S., et al. (2022) · Theranostics · doi:10.7150/thno.64805 · Cited by 124
High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D
Sim, M. J. W., Lu, J., Spencer, M., Hopkins, F., Tran, E., Rosenberg, S. A., Long, E. O., & Sun, P. D. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921964117 · Cited by 123
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 132
Wang, P., Chen, Y., & Wang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672677 · Cited by 156
Gfeller, D., Schmidt, J., Croce, G., Guillaume, P., Bobisse, S., Genolet, R., Queiroz, L., Cesbron, J., Racle, J., & Harari, A. (2023) · Cell Systems · doi:10.1016/j.cels.2022.12.002 · Cited by 117
Levine, A. J., Jenkins, N. A., & Copeland, N. G. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.11.009 · Cited by 121
Self-citationComputational Prediction and Validation of Tumor-Associated Neoantigens
Roudko, V., Greenbaum, B., & Bhardwaj, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00027 · Cited by 122
Self-citationThe Evolutionary Origins of Recurrent Pancreatic Cancer
Sakamoto, H., Attiyeh, M. A., Gerold, J. M., Makohon-Moore, A. P., Hayashi, A., Hong, J., Kappagantula, R., Zhang, L., Melchor, J. P., Reiter, J. G., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1508 · Cited by 119
Self-citationEvolutionary dynamics of neoantigens in growing tumors
Lakatos, E., Williams, M. J., Schenck, R. O., Cross, W. C. H., Househam, J., Zapata, L., Werner, B., Gatenbee, C., Robertson-Tessi, M., Barnes, C. P., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0687-1 · Cited by 121
Yousuf, S., Qiu, M., von Voithenberg, L. V., Hulkkonen, J., Mačinković, I., Schulz, A. R., Hartmann, D., Mueller, F., Mijatovic, M., Ibberson, D., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.05.036 · Cited by 137
Why is pancreatic cancer so deadly? The pathologist's view
Hruban, R. H., Gaida, M. M., Thompson, E., Hong, S., Noë, M., Brosens, L. A., Jongepier, M., Offerhaus, G. J. A., & Wood, L. D. (2019) · The Journal of Pathology · doi:10.1002/path.5260 · Cited by 115
“Recent evidence also demonstrates that the longest-term survivors of pancreatic cancers are associated with both the highest neoantigen levels (determined by whole-exome sequencing and in silico neoantigen prediction) and the most abundant CD8 T-cell responses, but importantly neither feature alone was linked to survi…”
BackgroundMasugi, Y., Abe, T., Ueno, A., Fujii‐Nishimura, Y., Ojima, H., Endo, Y., Fujita, Y., Kitago, M., Shinoda, M., Kitagawa, Y., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0291-z · Cited by 173
Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice
Delvecchio, F. R., Fincham, R. E. A., Spear, S., Clear, A. J., Roy-Luzarraga, M., Balkwill, F. R., Gribben, J. G., Bombardieri, M., Hodivala‐Dilke, K., Capasso, M., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.06.023 · Cited by 123
The Cancer Microbiome: Recent Highlights and Knowledge Gaps
Knippel, R. J., Drewes, J. L., & Sears, C. L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0324 · Cited by 110
Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target
Hartupee, C. D., Nagalo, B. M., Chabu, C. Y., Tesfay, M. Z., Coleman‐Barnett, J., West, J. T., & Moaven, O. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1287459 · Cited by 138
Epithelial and stromal co-evolution and complicity in pancreatic cancer
Hingorani, S. R. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00530-w · Cited by 108
TSNAdb: A Database for Tumor-Specific Neoantigens from Immunogenomics Data Analysis
Wu, J., Zhao, W., Zhou, B., Su, Z., Gu, X., Zhou, Z., & Chen, S. (2018) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2018.06.003 · Cited by 105
Miksch, R. C., Schoenberg, M. B., Weniger, M., Bösch, F., Ormanns, S., Mayer, B., Werner, J., Bazhin, A. V., & D’Haese, J. G. (2019) · Cancers · doi:10.3390/cancers11010039 · Cited by 115
Cimen Bozkus, C., Roudko, V., Finnigan, J. P., Mascarenhas, J., Hoffman, R., Iancu-Rubin, C., & Bhardwaj, N. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1356 · Cited by 105
Cancer cell-intrinsic mechanisms driving acquired immune tolerance
Ghorani, E., Swanton, C., & Quezada, S. A. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.004 · Cited by 126
TCRdb: a comprehensive database for T-cell receptor sequences with powerful search function
Chen, S.-Y., Yue, T., Lei, Q., & Guo, A.-Y. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa796 · Cited by 106
“The highly active of TCR-Seq technology in the past 10 years have enabled high-throughput and accurate identification of TCR repertoire, which is important with the advent of precision medicine (32) and immunotherapies (33).”
BackgroundImproved Risk Stratification by Circulating Tumor Cell Counts in Pancreatic Cancer
Effenberger, K. E., Schroeder, C., Hanssen, A., Wolter, S., zu Eulenburg, C., Tachezy, M., Gebauer, F., Izbicki, J. R., Pantel, K., & Bockhorn, M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0120 · Cited by 111
The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer
Chen, H., Chong, W., Teng, C., Yao, Y., Wang, X., & Li, X. (2019) · Cancer Science · doi:10.1111/cas.14113 · Cited by 116
Esprit, A., de Mey, W., Bahadur Shahi, R., Thielemans, K., Franceschini, L., & Breckpot, K. (2020) · Vaccines · doi:10.3390/vaccines8040776 · Cited by 103
Epigenetic modifiers as new immunomodulatory therapies in solid tumours
Aspeslagh, S., Morel, D., Soria, J., & Postel-Vinay, S. C. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy050 · Cited by 105
Weisberg, S. P., Carpenter, D. J., Chait, M., Dogra, P., Gartrell-Corrado, R. D., Chen, A. X., Campbell, S., Liu, W., Saraf, P., Snyder, M. E., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.056 · Cited by 103
Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine
Lomberk, G. A., Dusetti, N., Iovanna, J., & Urrutia, R. A. (2019) · Nature Communications · doi:10.1038/s41467-019-11812-7 · Cited by 113
Aghamajidi, A., & Vareki, S. M. (2022) · Cancers · doi:10.3390/cancers14153563 · Cited by 110
T cells in pancreatic cancer stroma
Goulart, M. R., Stasinos, K., Fincham, R. E. A., Delvecchio, F. R., & Kocher, H. M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i46.7956 · Cited by 119
The Role of Immunotherapy in Pancreatic Cancer
Mukherji, R., Debnath, D., Hartley, M. L., & Noel, M. S. (2022) · Current Oncology · doi:10.3390/curroncol29100541 · Cited by 116
Zhou, Q., Gong, N., Zhang, D., Li, J., Han, X. N., Dou, J., Huang, J., Zhu, K., Liang, P., Liang, X., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c09120 · Cited by 99
Falcomatà, C., Bärthel, S., Widholz, S. A., Schneeweis, C., Montero, J. J., Toska, A., Mir, J., Kaltenbacher, T., Heetmeyer, J., Swietlik, J. J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-021-00326-1 · Cited by 109
Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)
Chandana, S. R., Babiker, H. M., & Mahadevan, D. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1557145 · Cited by 115
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges
Kunimasa, K., & Goto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020597 · Cited by 113
Intestinal microbiota: a new force in cancer immunotherapy
Dai, Z., Zhang, J., Wu, Q., Fang, H., Shi, C., Li, Z., Lin, C., Tang, D., & Wang, D. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00599-6 · Cited by 104
Self-citationP53 and The Immune Response: 40 Years of Exploration—A Plan for the Future
Levine, A. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020541 · Cited by 97
“This was multiplied by the degree of homology of the peptide sequence to a known antigen derived from the microbiome, as listed in the immune epitope database (IEDB) [15,16].”
BackgroundMethodInfluentialSelf-citationMutation position is an important determinant for predicting cancer neoantigens
Capietto, A.-H., Jhunjhunwala, S., Pollock, S. B., Lupardus, P. J., Wong, J., Hänsch, L., Cevallos, J., Chestnut, Y., Fernandez, A., Lounsbury, N., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20190179 · Cited by 110
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Song, B., Yang, P., & Zhang, S. (2024) · 癌症:英文版 · doi:10.1002/cac2.12520 · Cited by 109
De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection
Beshnova, D., Ye, J., Onabolu, O., Moon, B., Zheng, W., Fu, Y.-X., Brugarolas, J., Lea, J., & Li, B. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz3738 · Cited by 98
Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy
Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 94
The perfect personalized cancer therapy: cancer vaccines against neoantigens
Aurisicchio, L., Pallocca, M., Ciliberto, G., & Palombo, F. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0751-1 · Cited by 97
DNA repair defects and implications for immunotherapy
Bever, K. M., & Le, D. T. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122010 · Cited by 101
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
Conway, J. R. W., Herrmann, D., Evans, T. J., Morton, J. P., & Timpson, P. (2018) · Gut · doi:10.1136/gutjnl-2018-316822 · Cited by 104
Zamora, A. E., Crawford, J. C., Allen, E. K., Guo, X.-Z. J., Bakke, J., Carter, R. A., Abdelsamed, H. A., Moustaki, A., Li, Y., Chang, T., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat8549 · Cited by 100
Self-citationBreast Cancer Vaccines: Disappointing or Promising?
Zhu, S., & Yu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828386 · Cited by 111
Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer
Rech, A. J., Balli, D., Mantero, A., Ishwaran, H., Nathanson, K. L., Stanger, B. Z., & Vonderheide, R. H. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0559 · Cited by 94
Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines
Vormehr, M., Türeci, Ö., & Sahin, U. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-042617-101816 · Cited by 92
Identification of new immune target and signaling for cancer immunotherapy
Narote, S., Desai, S. A., Patel, V. P., Deshmukh, R., Raut, N., & Dapse, S. (2025) · Cancer Genetics · doi:10.1016/j.cancergen.2025.03.004 · Cited by 110
Cancer vaccines and the future of immunotherapy
Pail, O., Lin, M. J., Anagnostou, T., Brown, B. D., & Brody, J. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00553-7 · Cited by 116
Chang, R. B., & Beatty, G. L. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mir0320-475r · Cited by 106
Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice
Selvanesan, B. C., Chandra, D., Quispe‐Tintaya, W., Jahangir, A., Patel, A. S., Meena, K., da Silva, R. A. A., Friedman, M., Gabor, L. R., Khouri, O. R., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abc1600 · Cited by 100
Self-citationMacrophage-Mediated Subversion of Anti-Tumour Immunity
Quaranta, V., & Schmid, M. C. (2019) · Cells · doi:10.3390/cells8070747 · Cited by 98
pTuneos: prioritizing tumor neoantigens from next-generation sequencing data
Zhou, C., Wei, Z., Zhang, Z., Zhang, B., Zhu, C., Chen, K., Chuai, G., Qu, S., Xie, L., Gao, Y., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0679-x · Cited by 97
Gartner, J. J., Parkhurst, M. R., Gros, A., Tran, E., Jafferji, M. S., Copeland, A. R., Hanada, K., Zacharakis, N., Lalani, A., Krishna, S., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00197-6 · Cited by 97
Huang, Y., Zhu, N., Zheng, X., Liu, Y., Lu, H., Yin, X., Hao, H., Tan, Y., Wang, D., Hu, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.785422 · Cited by 86
Gulhati, P., Schalck, A. P., Jiang, S., Shang, X., Wu, C., Hou, P., Ruiz, S. H., Soto, L. M. S., Parra, E. R., Ying, H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00500-z · Cited by 128
Affandi, A. J., Grabowska, J. A., Olesek, K., Venegas, M. L., Barbaria, A., Rodríguez, E., Mulder, P. P. G., Pijffers, H. J., Ambrosini, M., Kalay, H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006186117 · Cited by 95
Metadata
- Authors
- Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., Senbabaoglu, Y., Wells, D. K., Cary, C. I. O., Grbovic-Huezo, O., Attiyeh, M., Medina, B., Zhang, J., Loo, J., Saglimbeni, J., Abu-Akeel, M., Zappasodi, R., Riaz, N., Smoragiewicz, M., Kelley, Z. L., Basturk, O., Gönen, M., Levine, A. J., Allen, P. J., Fearon, D. T., Merad, M., Gnjatic, S., Iacobuzio-Donahue, C. A., Wolchok, J. D., DeMatteo, R. P., Chan, T. A., Greenbaum, B. D., Merghoub, T., & Leach, S. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Swim Across America (US)
- University of Cambridge (GB)
- Cold Spring Harbor Laboratory (US)
- Corresponding author
- Balachandran, Vinod P.
- ORCID
- Balachandran, Vinod P.
- Łuksza, Marta
- Zhao, Julia N.
- Makarov, Vladimir
- Herbst, Brian
- Bhanot, Umesh
- Wells, Daniel K.
- Grbovic-Huezo, Olivera
- Attiyeh, Marc
- Medina, Benjamin
- Zappasodi, Roberta
- Riaz, Nadeem
- Smoragiewicz, Martin
- Gönen, Mithat
- Levine, Arnold J.
- Fearon, Douglas T.
- Gnjatic, Sacha
- Wolchok, Jedd D.
- DeMatteo, Ronald P.
- Chan, Timothy A.
- Greenbaum, Benjamin D.
- Merghoub, Taha
- Leach, Steven D.
- Venue
- Nature
- Published
- 2017-11
- Volume
- 551
- Issue
- 7681
- Pages
- 512-516
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6145146
- OpenAlex
- W2767699537
- Cited by
- 1,191
- References
- 28
- Citations by year
- 2026: 89 · 2025: 114 · 2024: 119 · 2023: 178 · 2022: 169 · 2021: 153 · 2020: 135 · 2019: 132 · 2018: 94 · 2017: 6
- FWCI
- 44.60
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (23526, 17263, 15678)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Agence Nationale de la Recherche (ANR-18-CE14-0005)
- National Institutes of Health
- National Cancer Institute (P01CA087497, P30-CA-08748, R01CA190400, P30CA008748, T32CA009501, K12CA184746)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK097087)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- pancreatic ductal adenocarcinoma, long-term survival, neoantigens, CA125, CD8+ T cells, T cell immunity, immunogenicity, mutational burden, immune evasion
- MeSH terms
- Cancer Survivors, Exome Sequencing, Adenocarcinoma, Antigens, Neoplasm, Bacterial Proteins, Computer Simulation, Cross Reactions, Humans, Immunotherapy, Membrane Proteins, Pancreatic Neoplasms, Prognosis, T-Lymphocytes, Cytotoxic, Survival Analysis, CA-125 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.